Abstract: An exemplary substance is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Further, exemplary use of the substance as a drug carrier is provided for delivering into the brain, and a pharmaceutical composition containing the substance. Additionally, exemplary lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Exemplary blood-brain barrier permeable pharmaceutical composition is also provided which comprises a lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin, and a drug.

Abstract: An exemplary substance is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Further, exemplary use of the substance as a drug carrier is provided for delivering into the brain, and a pharmaceutical composition containing the substance. Additionally, exemplary lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Exemplary blood-brain barrier permeable pharmaceutical composition is also provided which comprises a lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin, and a drug.

Abstract: To provide a protein preparation which enables reduction of aggregation and a stable long-time preservation, in a protein preparation having a high concentration or a protein preparation susceptible to aggregation. The protein preparation is a gel preparation which is thixotropic and in which an included protein is protected from a physical or chemical stress, is inhibited from aggregation, and thereby stably exists.

Abstract: The purpose of the present invention is to provide a therapeutic agent that is more effective in refractory amyloidosis. More specifically, it is to provide a novel substance that is highly safe and is more excellent in a TTR protein amyloid fibril formation-inhibiting effect as compared with conventional therapeutic agents. Provided by the invention is an amyloid fibril suppressant comprising as an active ingredient a complex of a conjugate (GUG-?-CDE) of glucuronylglucosyl-?-cyclodextrin (GUG-?-CyD) and polyamide amine dendrimer having an alkylene diamine as the core with RNA that causes RNA interference in the mRNA of transthyretin (TTR). Also provided by the present invention is a pharmaceutical composition comprising the amyloid fibril suppressant for the prevention and/or treatment of amyloidosis.

Abstract: To provide a protein preparation which enables reduction of aggregation and a stable long-time preservation, in a protein preparation having a high concentration or a protein preparation susceptible to aggregation. The protein preparation is a gel preparation which is thixotropic and in which an included protein is protected from a physical or chemical stress, is inhibited from aggregation, and thereby stably exists.

Abstract: An initial object shape is set in a first process, a numeric fluid dynamic grid is generated on the surface of the object shape in a second process, and Navier-Stokes equations are numerically solved by numerical fluid dynamics based on the object and the grid generated with the object shape and an object surface pressure is determined in a third process. The noise generated by the object is a determined in a fourth process, by solving Curle's formula based on the object surface pressure, and noises are again determined in a fifth process by updating the object shape and repeating the first through fourth processes. By determining an object shape based on a shape which generates the smallest noise from among the noises determined by the fifth process, it becomes possible to determine a shape of the object as a shape capable of minimizing aerodynamic noise generated upon movement of the object through a fluid medium.

Abstract: A plurality of strain gages are installed on a structural body at n positions thereon. A concentrated reference load is applied to the structural body at one of the n positions and strains developed in the structural body at the respective n positions are measured when the concentrated reference load is applied to the structural body. The measured deformations are divided by the concentrated load reference to produce strains per unit load. The above process is repeated at each of the n positions to generate the practical equations given below: ##EQU1## where .kappa.11.about..kappa.nn represent strains per unit load, A1.about.An represent estimated loads (unknowns), and .epsilon.1.about..epsilon.n represent measured strain data.

Abstract: A cathode-ray tube socket substrate, which is to be used by being attached to a cathode-ray tube in a color cathode-ray tube display unit such as a color television receiver and the like, is disclosed. The tube socket substrate comprises at least a cathode-ray tube socket, associated color output circuitry around the cathode-ray tube, and a high-voltage variable resistor, all three elements being mounted on an insulating substrate, on which is provided a film resistor forming a resistance part of the high-voltage variable resistor, and a plurality of corresponding terminal electrodes. Connected to these terminal electrodes are pin terminals for the focusing electrode of the cathode-ray tube socket, and a terminal part onto which is connected an output terminal of a rectifier circuit.